# Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

> **NCT00818623** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 172 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT00818623
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2023-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818623, "Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00818623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*